497.83
7.06 (1.44%)
| Previous Close | 490.77 |
| Open | 488.47 |
| Volume | 243,474 |
| Avg. Volume (3M) | 498,445 |
| Market Cap | 13,985,538,048 |
| Price / Earnings (TTM) | 37.01 |
| Price / Earnings (Forward) | 33.11 |
| Price / Sales | 6.83 |
| Price / Book | 79.97 |
| 52 Weeks Range | |
| Earnings Date | 20 Oct 2025 |
| Profit Margin | 19.31% |
| Operating Margin (TTM) | 20.32% |
| Diluted EPS (TTM) | 13.10 |
| Quarterly Revenue Growth (YOY) | 9.30% |
| Quarterly Earnings Growth (YOY) | 11.70% |
| Total Debt/Equity (MRQ) | 25.33% |
| Current Ratio (MRQ) | 0.730 |
| Operating Cash Flow (TTM) | 581.97 M |
| Levered Free Cash Flow (TTM) | 433.28 M |
| Return on Assets (TTM) | 15.44% |
| Return on Equity (TTM) | 65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Medpace Holdings, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.60 |
|
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 20.55% |
| % Held by Institutions | 91.47% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blackrock, Inc. | 30 Jun 2025 | 2,464,690 |
| Vanguard Group Inc | 30 Jun 2025 | 2,390,623 |
| Wasatch Advisors Lp | 30 Jun 2025 | 945,814 |
| Mawer Investment Management Ltd. | 30 Jun 2025 | 817,432 |
| State Street Corp | 30 Jun 2025 | 706,777 |
| Aqr Capital Management Llc | 30 Jun 2025 | 621,184 |
| Baillie Gifford & Co | 30 Jun 2025 | 522,293 |
| Bessemer Group Inc | 30 Jun 2025 | 507,672 |
| Td Asset Management Inc | 30 Jun 2025 | 457,645 |
| Epoch Investment Partners, Inc. | 30 Jun 2025 | 445,231 |
| Riverbridge Partners Llc | 30 Jun 2025 | 434,024 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 510.00 (Mizuho, 2.45%) | Buy |
| Median | 450.00 (-9.61%) | |
| Low | 305.00 (UBS, -38.73%) | Sell |
| Average | 434.56 (-12.71%) | |
| Total | 1 Buy, 6 Hold, 2 Sell | |
| Avg. Price @ Call | 449.92 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 09 Sep 2025 | 450.00 (-9.61%) | Hold | 485.59 |
| Rothschild & Co | 03 Sep 2025 | 474.00 (-4.79%) | Hold | 481.23 |
| UBS | 29 Jul 2025 | 305.00 (-38.73%) | Sell | 447.92 |
| Mizuho | 25 Jul 2025 | 510.00 (2.44%) | Buy | 447.49 |
| Baird | 23 Jul 2025 | 490.00 (-1.57%) | Hold | 437.41 |
| Barclays | 23 Jul 2025 | 450.00 (-9.61%) | Hold | 437.41 |
| 24 Jun 2025 | 300.00 (-39.74%) | Hold | 315.28 | |
| Deutsche Bank | 23 Jul 2025 | 430.00 (-13.63%) | Hold | 437.41 |
| TD Cowen | 23 Jul 2025 | 366.00 (-26.48%) | Sell | 437.41 |
| Truist Securities | 23 Jul 2025 | 436.00 (-12.42%) | Hold | 437.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURWIG SUSAN E | - | 481.23 | -10,000 | -4,812,300 |
| Aggregate Net Quantity | -10,000 | |||
| Aggregate Net Value ($) | -4,812,300 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 481.23 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BURWIG SUSAN E | Officer | 03 Sep 2025 | Sell (-) | 10,000 | 481.23 | 4,812,300 |
| Date | Type | Details |
|---|---|---|
| 21 Jul 2025 | Announcement | Medpace Holdings, Inc. Reports Second Quarter 2025 Results |
| 23 Jun 2025 | Announcement | Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |